These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 27455963)

  • 1. Comparison of Statistical Approaches for Dealing With Immortal Time Bias in Drug Effectiveness Studies.
    Karim ME; Gustafson P; Petkau J; Tremlett H;
    Am J Epidemiol; 2016 Aug; 184(4):325-35. PubMed ID: 27455963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of statistical approaches dealing with time-dependent confounding in drug effectiveness studies.
    Karim ME; Petkau J; Gustafson P; Platt RW; Tremlett H;
    Stat Methods Med Res; 2018 Jun; 27(6):1709-1722. PubMed ID: 27659168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immortal time bias in drug safety cohort studies: spontaneous abortion following nonsteroidal antiinflammatory drug exposure.
    Daniel S; Koren G; Lunenfeld E; Levy A
    Am J Obstet Gynecol; 2015 Mar; 212(3):307.e1-6. PubMed ID: 25265406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immortal time bias in the study of effectiveness of interferon-beta in multiple sclerosis.
    Renoux C; Suissa S
    Ann Neurol; 2008 Jul; 64(1):109-10; author reply 110. PubMed ID: 18668635
    [No Abstract]   [Full Text] [Related]  

  • 5. Dealing With Treatment-Confounder Feedback and Sparse Follow-up in Longitudinal Studies: Application of a Marginal Structural Model in a Multiple Sclerosis Cohort.
    Karim ME; Tremlett H; Zhu F; Petkau J; Kingwell E
    Am J Epidemiol; 2021 May; 190(5):908-917. PubMed ID: 33125039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating inverse probability weights using super learner when weight-model specification is unknown in a marginal structural Cox model context.
    Karim ME; Platt RW;
    Stat Med; 2017 Jun; 36(13):2032-2047. PubMed ID: 28219110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immortal time bias in observational studies of time-to-event outcomes.
    Jones M; Fowler R
    J Crit Care; 2016 Dec; 36():195-199. PubMed ID: 27546771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical methods for elimination of guarantee-time bias in cohort studies: a simulation study.
    Cho IS; Chae YR; Kim JH; Yoo HR; Jang SY; Kim GR; Nam CM
    BMC Med Res Methodol; 2017 Aug; 17(1):126. PubMed ID: 28830373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of heterogeneity in the association between interferon beta and disability progression in multiple sclerosis: an observational study.
    Shirani A; Zhao Y; Karim ME; Petkau J; Gustafson P; Evans C; Kingwell E; van der Kop ML; Oger J; Tremlett H
    Eur J Neurol; 2014 Jun; 21(6):835-44. PubMed ID: 24351059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methodological evaluation of bias in observational coronavirus disease 2019 studies on drug effectiveness.
    Martinuka O; von Cube M; Wolkewitz M
    Clin Microbiol Infect; 2021 Jul; 27(7):949-957. PubMed ID: 33813117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immortal time bias in pharmaco-epidemiology.
    Suissa S
    Am J Epidemiol; 2008 Feb; 167(4):492-9. PubMed ID: 18056625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Issues regarding 'immortal time' in the analysis of the treatment effects in observational studies.
    Liu J; Weinhandl ED; Gilbertson DT; Collins AJ; St Peter WL
    Kidney Int; 2012 Feb; 81(4):341-50. PubMed ID: 22089946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.
    Kappos L; Freedman MS; Polman CH; Edan G; Hartung HP; Miller DH; Montalbán X; Barkhof F; Radü EW; Metzig C; Bauer L; Lanius V; Sandbrink R; Pohl C;
    Lancet Neurol; 2009 Nov; 8(11):987-97. PubMed ID: 19748319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNbeta exposure in multiple sclerosis.
    Trojano M; Russo P; Fuiani A; Paolicelli D; Di Monte E; Granieri E; Rosati G; Savettieri G; Comi G; Livrea P;
    Mult Scler; 2006 Oct; 12(5):578-85. PubMed ID: 17086903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of the landmark method to address immortal person-time bias in comparative effectiveness research: a simulation study.
    Mi X; Hammill BG; Curtis LH; Lai EC; Setoguchi S
    Stat Med; 2016 Nov; 35(26):4824-4836. PubMed ID: 27350312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.
    He A; Spelman T; Jokubaitis V; Havrdova E; Horakova D; Trojano M; Lugaresi A; Izquierdo G; Grammond P; Duquette P; Girard M; Pucci E; Iuliano G; Alroughani R; Oreja-Guevara C; Fernandez-Bolaños R; Grand'Maison F; Sola P; Spitaleri D; Granella F; Terzi M; Lechner-Scott J; Van Pesch V; Hupperts R; Sánchez-Menoyo JL; Hodgkinson S; Rozsa C; Verheul F; Butzkueven H; Kalincik T;
    JAMA Neurol; 2015 Apr; 72(4):405-13. PubMed ID: 25665031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.
    Shirani A; Zhao Y; Karim ME; Evans C; Kingwell E; van der Kop ML; Oger J; Gustafson P; Petkau J; Tremlett H
    JAMA; 2012 Jul; 308(3):247-56. PubMed ID: 22797642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addressing immortal time bias in precision medicine: Practical guidance and methods development.
    Weymann D; Krebs E; Regier DA
    Health Serv Res; 2024 Sep; ():. PubMed ID: 39225454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immortal time bias for life-long conditions in retrospective observational studies using electronic health records.
    Tyrer F; Bhaskaran K; Rutherford MJ
    BMC Med Res Methodol; 2022 Mar; 22(1):86. PubMed ID: 35350993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.
    Trojano M; Pellegrini F; Paolicelli D; Fuiani A; Zimatore GB; Tortorella C; Simone IL; Patti F; Ghezzi A; Portaccio E; Rossi P; Pozzilli C; Salemi G; Lugaresi A; Bergamaschi R; Millefiorini E; Clerico M; Lus G; Vianello M; Avolio C; Cavalla P; Iaffaldano P; Direnzo V; D'Onghia M; Lepore V; Livrea P; Comi G; Amato MP;
    J Neurol Sci; 2009 Nov; 286(1-2):109-13. PubMed ID: 19615696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.